Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q4 Loss
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $25.20 -0.4%
EPS Growth %: -62.5%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
CRMT, FOMI, FLES, More
EPS Growth %: -62.5%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $588 thousand versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Pharmaceuticals (ACAD) PT Raised to $36 at Canaccord
- Global-e completes $350M acquisition of Passport logistics firm
- Innovex closes $95M acquisition of TCO Group AS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
